Sign in Subscribe
Novo Nordisk A/S

Novo Nordisk Announces New Data on Investigational Oral Semaglutide 25 mg and Innovative Pipeline

Strategic Insights

— 2 min read

Novo Nordisk is expanding the evidence base on the weight loss efficacy and cardiometabolic profile of their investigational oral semaglutide 25 mg, a new research has revealed. The new data is part of 23 abstracts to be presented at ObesityWeek from 4-7 November in Atlanta, US. The presentations will add to the strong momentum of their obesity portfolio and showcase the innovative pipeline with new data for people living with obesity.

The OASIS 4 trial highlights include: Investigating improvements in blood sugar and cardiovascular risk factors, examining the efficacy of semaglutide across formulations in women's health, and comparing the efficacy of semaglutide in a pill with injectable semaglutide (Wegovy).

Key Takeaways:

  • Novo Nordisk is presenting new data on investigational oral semaglutide 25 mg, a new weight loss treatment for adults with obesity or overweight.
  • The OASIS 4 trial explores improvements in glycemic parameters and cardiovascular risk factors for people with obesity or overweight treated with once-daily oral semaglutide 25 mg.
  • The study also examines the efficacy of semaglutide in reducing body weight in women in pre- and post-menopausal stages, and another assesses improved physical function based on patient-reported outcomes data.
  • Novo Nordisk's OASIS 4 trial also compares the efficacy of semaglutide in a pill with injectable semaglutide (Wegovy) in a post hoc analysis.
  • Additional data from the REDEFINE 1 trial highlights the cardiovascular risk reduction potential of investigational CagriSema and examines the percentage of people treated with CagriSema who achieved clinically relevant treatment targets for obesity management.
  • Select Novo Nordisk abstracts to be presented at ObesityWeek 2025 will cover a range of topics, including the efficacy of oral semaglutide 25 mg, the impact of semaglutide on physical function, and the effects of CagriSema on body composition, muscle strength, and physical function.

Statistics:

  • 23 abstracts will be presented at ObesityWeek 2025.
  • The presentations will cover a range of topics, including the efficacy of investigational oral semaglutide 25 mg.
  • The OASIS 4 trial explored improvements in glycemic parameters and cardiovascular risk factors for people with obesity or overweight treated with once-daily oral semaglutide 25 mg.
  • The study included data on over 1,500 participants.
  • The data on body weight reductions showed a significant difference between the treatment groups.

Sources:

  • 1. Rubino D, Birkhan O, Garvey TW, et al. Improvements in Glycemic Parameters and Cardiovascular Risk Factors with Oral Semaglutide 25 mg. Oral presentation presented at ObesityWeek 2025; 4-7 November 2025; Georgia World Congress Center, Atlanta, GA, US. Presentation 026.
  • 2. Andrade MDH, Dunsmoor-Su R, Huvinen E, et al. Semaglutide Reduces Body Weight Regardless of Menopause Status: STEP and OASIS 4 Post Hoc Analysis. Poster presentation presented at ObesityWeek 2025; 4-7 November 2025; Georgia World Congress Center, Atlanta, GA, US. Poster 316.
  • 3. Rubino D, Birkhan O, Garvey TW, et al. Efficacy of Oral Semaglutide 25 mg in People with Overweight or Obesity and Poor Physical Function. Poster presentation presented at ObesityWeek 2025; 4-7 November 2025; Georgia World Congress Center, Atlanta, GA, US. Poster 111.
  • 4. Verma S, Böttcher M, Brown P, et al. CagriSema Reduces Predicted ASCVD Risk in Adults With Overweight or Obesity: the REDEFINE 1 Trial. Poster presentation presented at ObesityWeek 2025; 4-7 November 2025; Georgia World Congress Center, Atlanta, GA, US. Poster 711.
  • 5. Busetto L, Contreras CO, Christensen MH, et al. CagriSema and achievement of BMI and waist-to-height ratio treatment targets: REDEFINE 1. Poster presentation presented at ObesityWeek 2025; 4-7 November 2025; Georgia World Congress Center, Atlanta, GA, US. Poster 478.
  • 6. Le RouxCW, Garvey TW, Kolnes JK, et al. STEP UP: Efficacy of Semaglutide in Obesity Treatment Targets and Cardiovascular Risk Thresholds. Oral presentation presented at ObesityWeek 2025; 4-7 November 2025; Georgia World Congress Center, Atlanta, GA, US. Presentation 059.

Read more